Overview

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Status:
Recruiting

Trial end date:
2027-10-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor [HR]-negative and HR-positive) unresectable and/or metastatic breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Daiichi Sankyo

Collaborator:

AstraZeneca

Treatments:

Trastuzumab
Trastuzumab deruxtecan